The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Rather interestingly via the old twitter; T212 have stated they will give cash to holders to buy accustoem. When asked if they will have accustem added to their platform they replied yes. However they have stopped responding since being challenged on why they wouldn't just issue the shares
Thanks guys much obliged.
Being a newbie it’s good to know that they are aware of the situation.
World’s worst worrier.
Dave
4.29
The response i got from freetrade just now.
Hi xxxx??
Thanks for your patience here - If approved, the Spin off of StemPrintER into a new company, AccuStem Sciences is due to become effective at the end of the month. We plan to allocate the new shares to entitled Tiziana holders once we have received these new shares so, as the Company outlines, this may not be until some time after the demerger has become effective. Whilst we plan to allocate the new shares based on the information currently available, we cannot confirm until more information is released regarding the new shares and admission for listing. An in-app notification will be sent to eligible holders closer to the time with more information.
Is there anything else I can help you with?
Best
Ed
there's also talk in the T212 community forum:
https://community.**************/t/demerger-process/11158/26
with an update yesterday to say the shares will be sold at market on the day they are listed and cash transferred rather than at the time of the split:
"We will do our best to be ready with the functionality of transferring shares instead of paying out cash by the end of the year and hopefully we will be able to rely on it for the execution of this event. If not, the newly issued shares will be sold at the market (once they are tradable on the exchange) and the proceeds will be distributed in the days following trade commencement."
I suspect T212 and Freetrade are in the same boat in this regard.
look_over_there
Thanks for trying to help out the/this 212s
just had a message from Freetrade, they still dont know if you'll get the shares or not...
"Following approval, we plan to allocat the Accustem Sciences shares to entitled Tiziana holders once we received the new shares later this year. Whilstwe plan to allocate new shares based on the information currently available, once more information is released regarding the new shares and the application for listing on the LSE, further due diligence will be conducted to determine wheterh Freetrade can support Accustem Sciences shares and issue to customer portfolios. An ip-app notification will be sent to eligible holders closer to the time with more information to confirm."
Pinged a message to T212 in the app chat and they said a decision hadn't been reached yet...
Funnily enough I got the same response yesterday. Still waiting on a definitive answer which I'm assured I'll get. We'll see.
I have a small holding in Freetrade and asked the question a few weeks ago. They were rather non-commital just that their Corporate Actions Officer would be in touch nearer the time.
I don't know it will reach 177p, but my hope is that will revisit 200 close to the demerger.
How do you know they will reach 1.77. That is my buy in also. Bought at 177. Went to 305 the next day. Then watched thousands of pounds sink
You can trade these on freeteade also, anyone holding in there? Perhaps they have a better clue how to solve this issue?
I will drop an email and see what they say.
More later.
All I'm saying is that this T212 policy is a rip off. I for one intend to sell my shares before the demerger, hopefully above my 177p entry point and re-enter after the demerger both in TILS and Accustem.
can't. Live abroad
Good morning Luk_32
As I always say this is just an idea not even my view as I know little, compared to others.
Let’s say we on 212 only get 2p an accustem share, then when it goes live it’s 50 p for everyone else, for example, wouldn’t you feel a bit, more than a bit ripped off? We all paid for our Tils shares just like anyone else. I don’t understand where the problem is in not giving everyone shares.
Maybe this 2p value is as below. I copied it from the internet. Maybe not.
If you have any views, please let me know. Good or bad
The Value of Ordinary Shares
In many jurisdictions, ordinary shares have a stated "par value" or face value, but this is a technicality and is often set at a few pennies per share. Market forces, the value of the underlying business, and investor sentiment determine the market price that investors pay for ordinary shares.
A famous example is Berkshire Hathaway Inc. (BRK.A), whose Class A common shares have a par value of $5 but trade above $325,000 per share as of early September 2020.
It takes 10 mins to open an isa with ii, hl etc, you still gave time to sell and rebuy before any major price movement occurs andhet tje actual benefit of stem shares credited to your account.
B0LL0X to t212.
I don't really understand why you are concerned about the market price of Accustem shares.
As we stand today, T212 will not give us the Accustem shares, but the value at a given moment. My guess is that moment is 30 October, the demerger date. At that moment, the Accustem will have a market cap of 3 mil and a share value of 2p, as stated in the RNS. This is what T212 will pay us for our Accustem shares. I wish I was wrong, but this is what I believe will happen.
More, do you really think that Accustem will be listed on T212?
Don,t think anybody knows at the moment for sure, but some of the more knowlegable people on here might be able to give you/us an idea.
Noob here. So when do we expect to actually know the value of the stem share price?
I would question if people have put a value on stemprinter since it was made public. Just because the company haven’t put an asset value on their books, I think many have invested due it being part of their portfolio.
this was back in July Tiziana Life Sciences PLC’s (LON:TILS, NASDAQ:TLSA) diagnostics spinout could be worth significantly more than Tiziana itself, according to a leading Wall Street healthcare analyst.
The documentation around the planned demerger of StemPrintER is expected to go out to investors shortly after the company’s AGM on July 16.
And as a publicly-listed business, it is worth around 10% of the value of Genomic Health, the nearest competitor, HC Wainwright’s Raghuram Selvaraju reckons.
On that basis then its value should be in the region of US$280mln, which compares with Tiziana’s current market capitalization of US$226mln.
now October isTils worth more than 95p with out stem !!
I have said this several times that the market has accredited stemprinter with no value as its quite unique. So i really cant see how they can drop the tils sp when accustem has no value. Now theres one or two on here that say initially its worth 3 mill and i get that. But i dont get tils dropping to a £1 after demerging. But thats my thoughts and everyones entitled there opinions and yes i do expect the MM's to play there games as well. So theres 3 and a bit weeks to find out who's right or wrong whatever the outcome it doesnt really matter in the realms of todays covid crisis. Gla ave a great day
.
Thanks for all the input. Lots to think about.
To be honest I don't think I would be too concerned if I wasn't using 212
because Tils looks like a great investment to me.
Whatever happens over October I'll be happier to invest when they are seperate companies.
Didn't know this was going to be so convoluted. (now there's a word)
Thanks again
Dave
I honestly expect Stem to underperform an receive a 70-80p valuation. As someone mentioned there is a lot of work to be done.
I hope once we are rid of Stem our SP will remain around £1 until the Results from the COVID trials, which if positive, could see us rise above £2.
Going in to 2021 I’m expecting big things as we have an abundance of data due. Once Stem is gone we can finally concentrate on the crown jewel.
Bright light .. how did you arrive at that valuation . Thanks
the way I see it the spilt Stem price value should be in the region of £220mln, will range between 110 &114p
as for Taziana after spilt market capitalization of value ranging 85& 95p, so combined maximum price 209p .